Structure-activity relationship study of N⁶-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: development of highly selective D3 dopamine receptor agonists along with a highly potent D2/D3 agonist and their pharmacological characterization

In our effort to develop multifunctional drugs against Parkinson's disease, a structure-activity-relationship study was carried out based on our hybrid molecular template targeting D2/D3 receptors. Competitive binding with [(3)H]spiroperidol was used to evaluate affinity (K(i)) of test compounds. Functional activity of selected compounds in stimulating [(35)S]GTPγS binding was assessed in CHO cells expressing either human D2 or D3 receptors. Our results demonstrated development of highly selective compounds for D3 receptor (for (-)-40K(i), D3 = 1.84 nM, D2/D3 = 583.2; for (-)-45K(i), D3 = 1.09 nM, D2/D3 = 827.5). Functional data identified (-)-40 (EC(50), D2 = 114 nM, D3 = 0.26 nM, D2/D3 = 438) as one of the highest D3 selective agonists known to date. In addition, high affinity, nonselective D3 agonist (-)-19 (EC(50), D2 = 2.96 nM and D3 = 1.26 nM) was also developed. Lead compounds with antioxidant activity were evaluated using an in vivo PD animal model.

[1]  Aloke K. Dutta,et al.  Novel D3 dopamine receptor‐preferring agonist D‐264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine and lactacystin , 2010, Journal of neuroscience research.

[2]  Maurizio Recanatini,et al.  Multi-target-directed ligands to combat neurodegenerative diseases. , 2008, Journal of medicinal chemistry.

[3]  K. Jellinger,et al.  The Neuropathologic Basis of Different Clinical Subgroups of Parkinson's Disease , 1991, Journal of neuropathology and experimental neurology.

[4]  M. Martres,et al.  [Gene cloning of human dopaminergic D3 receptor and identification of its chromosome]. , 1990, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

[5]  D. Accili,et al.  Structural Organization of the Murine D3 Dopamine Receptor Gene , 1995, Journal of neurochemistry.

[6]  S. Przedborski,et al.  Oxidative Stress in Parkinson's Disease , 2008, Annals of the New York Academy of Sciences.

[7]  J. Joyce,et al.  Distribution of Dopamine D3 Receptor Expressing Neurons in the Human Forebrain: Comparison with D2 Receptor Expressing Neurons , 1999, Neuropsychopharmacology.

[8]  M. Millan,et al.  S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: II. Actions in Rodent, Primate, and Cellular Models of Antiparkinsonian Activity in Comparison to Ropinirole , 2004, Journal of Pharmacology and Experimental Therapeutics.

[9]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[10]  Philip Seeman,et al.  Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine , 1991, Nature.

[11]  T. Sherer,et al.  Pathogenesis of Parkinson's disease. , 2001, Current opinion in investigational drugs.

[12]  J. Andersen,et al.  Dopamine D2/D3 Agonists with Potent Iron Chelation, Antioxidant and Neuroprotective Properties: Potential Implication in Symptomatic and Neuroprotective Treatment of Parkinson’s Disease , 2011, ChemMedChem.

[13]  M. Reith,et al.  Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity. , 2008, Journal of medicinal chemistry.

[14]  C. Chignell,et al.  Reaction of melatonin and related indoles with hydroxyl radicals: EPR and spin trapping investigations. , 1997, Free radical biology & medicine.

[15]  Bruno Giros,et al.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics , 1990, Nature.

[16]  M. Mouradian.  Recent advances in the genetics and pathogenesis of Parkinson disease , 2002, Neurology.

[17]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[18]  M. Reith,et al.  Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models. , 2010, Journal of medicinal chemistry.

[19]  A. Carlsson,et al.  3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists , 1957, Nature.

[20]  P. Strange.  New insights into dopamine receptors in the central nervous system , 1993, Neurochemistry International.

[21]  P. O'Suilleabhain.  Movement Disorders: Neurologic Principles and Practice , 1997 .

[22]  J. Kebabian,et al.  Multiple receptors for dopamine , 1979, Nature.

[23]  M. Reith,et al.  Synthesis and biological characterization of novel hybrid 7-[[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors. , 2004, Bioorganic & medicinal chemistry.

[24]  Susan R. George,et al.  Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1 , 1991, Nature.

[25]  Robert R Luedtke,et al.  N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity. , 2011, Journal of medicinal chemistry.

[26]  V. Menon,et al.  Antioxidant activity of an aminothiazole compound: possible mechanisms. , 2008, Chemico-biological interactions.

[27]  N. Hattori,et al.  [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease]. , 2004, Rinsho shinkeigaku = Clinical neurology.

[28]  S. Cragg,et al.  Dopamine receptors--physiological understanding to therapeutic intervention potential. , 1999, Pharmacology & therapeutics.

[29]  D. Grandy,et al.  Cloning of the cDNA and gene for a human D2 dopamine receptor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[31]  H. Shertzer,et al.  Molecular modeling parameters predict antioxidant efficacy of 3-indolyl compounds , 1996, Archives of Toxicology.

[32]  T. Dawson,et al.  Molecular Pathways of Neurodegeneration in Parkinson's Disease , 2003, Science.

[33]  M. Reith,et al.  Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol: effect on affinity and selectivity for dopamine D3 receptor. , 2009, Bioorganic & medicinal chemistry.

[34]  Daewoo Lee,et al.  Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by alpha-synuclein. , 2007, The European journal of neuroscience.

[35]  J. D. Parkes,et al.  "ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPY , 1976, The Lancet.

[36]  Andrew B West,et al.  Molecular pathophysiology of Parkinson's disease. , 2005, Annual review of neuroscience.

[37]  Peter Gmeiner,et al.  The structural evolution of dopamine D3 receptor ligands: structure-activity relationships and selected neuropharmacological aspects. , 2006, Pharmacology & therapeutics.

[38]  D. Grandy,et al.  Molecular diversity of the dopamine receptors. , 1993, Annual review of pharmacology and toxicology.

[39]  Bruce A. Yankner,et al.  Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.

[40]  A. Bindoli,et al.  Biochemical and toxicological properties of the oxidation products of catecholamines. , 1992, Free radical biology & medicine.

[41]  M. Reith,et al.  Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action. , 2008, Journal of medicinal chemistry.

[42]  Daewoo Lee,et al.  Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by α‐synuclein , 2007 .

[43]  R. Mccall,et al.  Sumanirole, a Highly Dopamine D2-Selective Receptor Agonist: In Vitro and in Vivo Pharmacological Characterization and Efficacy in Animal Models of Parkinson's Disease , 2005, Journal of Pharmacology and Experimental Therapeutics.

[44]  M. Reith,et al.  Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkins , 2010, Journal of medicinal chemistry.

[45]  D. Sulzer,et al.  Interplay between Cytosolic Dopamine, Calcium, and α-Synuclein Causes Selective Death of Substantia Nigra Neurons , 2009, Neuron.

[46]  B. Patil,et al.  Radical scavenging and cytochrome P450 3A4 inhibitory activity of bergaptol and geranylcoumarin from grapefruit. , 2007, Bioorganic & medicinal chemistry.